CN103989753B - 一种治疗良性前列腺增生的药物组合物 - Google Patents
一种治疗良性前列腺增生的药物组合物 Download PDFInfo
- Publication number
- CN103989753B CN103989753B CN201410239665.8A CN201410239665A CN103989753B CN 103989753 B CN103989753 B CN 103989753B CN 201410239665 A CN201410239665 A CN 201410239665A CN 103989753 B CN103989753 B CN 103989753B
- Authority
- CN
- China
- Prior art keywords
- alfuzosin
- pharmaceutical composition
- semen plantaginis
- ethanol extraction
- prostatic hyperplasia
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 27
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 21
- WNMJYKCGWZFFKR-UHFFFAOYSA-N alfuzosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 WNMJYKCGWZFFKR-UHFFFAOYSA-N 0.000 claims abstract description 50
- 210000000582 semen Anatomy 0.000 claims abstract description 46
- 229960004607 alfuzosin Drugs 0.000 claims abstract description 45
- 238000002481 ethanol extraction Methods 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims abstract description 17
- 239000008187 granular material Substances 0.000 claims abstract description 10
- 239000002775 capsule Substances 0.000 claims abstract description 7
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 239000012535 impurity Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 claims description 2
- 229940077388 benzenesulfonate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000000203 mixture Substances 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 7
- 238000011474 orchiectomy Methods 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- YTNKWDJILNVLGX-UHFFFAOYSA-N alfuzosin hydrochloride Chemical compound [H+].[Cl-].N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(C)CCCNC(=O)C1CCCO1 YTNKWDJILNVLGX-UHFFFAOYSA-N 0.000 description 13
- 229960003103 alfuzosin hydrochloride Drugs 0.000 description 13
- 210000002307 prostate Anatomy 0.000 description 13
- 241000700159 Rattus Species 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 239000002671 adjuvant Substances 0.000 description 7
- 238000009472 formulation Methods 0.000 description 7
- 238000003304 gavage Methods 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 230000001629 suppression Effects 0.000 description 7
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000003932 urinary bladder Anatomy 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 210000001550 testis Anatomy 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 1
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-Phenylethanol Natural products OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 1
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010064022 Prostatic mass Diseases 0.000 description 1
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 229940099393 alfuzosin hydrochloride 10 mg Drugs 0.000 description 1
- 229940036073 alfuzosin hydrochloride 2.5 mg Drugs 0.000 description 1
- 102000004305 alpha Adrenergic Receptors Human genes 0.000 description 1
- 108090000861 alpha Adrenergic Receptors Proteins 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 206010013990 dysuria Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- -1 phenethyl alcohol glycosides Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 229960001712 testosterone propionate Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
- 230000004567 urinary tract smooth muscle contraction Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410239665.8A CN103989753B (zh) | 2014-05-30 | 2014-05-30 | 一种治疗良性前列腺增生的药物组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201410239665.8A CN103989753B (zh) | 2014-05-30 | 2014-05-30 | 一种治疗良性前列腺增生的药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103989753A CN103989753A (zh) | 2014-08-20 |
CN103989753B true CN103989753B (zh) | 2016-04-27 |
Family
ID=51304254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201410239665.8A Expired - Fee Related CN103989753B (zh) | 2014-05-30 | 2014-05-30 | 一种治疗良性前列腺增生的药物组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103989753B (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106617053A (zh) * | 2016-12-01 | 2017-05-10 | 西安交通大学医学院第附属医院 | 一种防治前列腺炎及前列腺增生的保健食品及制备方法 |
-
2014
- 2014-05-30 CN CN201410239665.8A patent/CN103989753B/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN103989753A (zh) | 2014-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102172363A (zh) | 包含强心苷的scf提取物 | |
CN103702975B (zh) | 反式-氯米芬代谢物及其用途 | |
Kajaria et al. | Anti-histaminic, mast cell stabilizing and bronchodilator effect of hydroalcoholic extract of polyherbal compound–Bharangyadi | |
CN113694175A (zh) | 苦参碱基离子液体芋螺毒素多肽溶液、制剂及其制备方法与应用 | |
EP3518936A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
CN105288073A (zh) | 一种润肠通便、改善肠胃功能的保健食品 | |
CN103989753B (zh) | 一种治疗良性前列腺增生的药物组合物 | |
EP3716969A1 (en) | Pharmaceutical combination comprising lsz102 and alpelisib | |
RU2017112748A (ru) | Композиции онапристона пролонгированного действия и способы | |
CN109528806B (zh) | 南瓜籽油中甾醇组合物及其应用和治疗前列腺增生药物 | |
KR101072175B1 (ko) | 데커신 및/또는 데커시놀 안젤레이트, 또는 데커신및/또는 데커시놀 안젤레이트를 유효성분으로 하는당귀추출물을 포함하는 배뇨장애 치료제 및 부종 치료제조성물 | |
CN1209111C (zh) | 抗孕激素在细胞中诱导编程性细胞死亡的应用 | |
KR20200091925A (ko) | 칠엽수 추출물을 포함하는 조성물 | |
EP3709997A1 (en) | Pharmaceutical combination comprising lsz102 and ribociclib | |
KR101411408B1 (ko) | 천연 추출물과 알파차단제를 함유하는 전립선 질환 예방 및 치료용 약학조성물 | |
CN1853708B (zh) | 中药红豆蔻及其提取物的制药新用途 | |
CN111281867B (zh) | 一种治疗多囊卵巢综合征的药物及其制备方法 | |
CN104706639B (zh) | 一种治疗雄性勃起功能障碍的药物组合物及其用途 | |
TW201211061A (en) | Pharmaceutical composition for treating cancers | |
KR20150128622A (ko) | 클로미프라민 함유 맛 차폐된 구강 투여용 약학 제제 | |
CN101104024A (zh) | 一种用于治疗良性前列腺增生症的中药组合物的制备及其应用 | |
WO2019037671A1 (zh) | 一种治疗癌症的联合用药物 | |
CN101455724A (zh) | 一种治疗皮肤瘙痒、湿疹、妇科炎症的药用组合物 | |
CN104069179B (zh) | 一种皮肤抗菌药物组合物及其制备方法和用途 | |
CN111714499B (zh) | 一种用于治疗多囊卵巢综合征的药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
CB03 | Change of inventor or designer information |
Inventor after: Luan Jie Inventor before: Han Hui Inventor before: Li Xuemei |
|
COR | Change of bibliographic data | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160316 Address after: 266300 Department of Urology, Jiaozhou Central Hospital, Qingdao, Shandong, China Applicant after: Luan Jie Address before: 266555, No. 3, building 30, 102 Mount Lu Road, Huangdao District, Qingdao, Shandong, 702 Applicant before: Li Xuemei |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Zhang Zhicai Inventor before: Luan Jie |
|
CB03 | Change of inventor or designer information | ||
TR01 | Transfer of patent right |
Effective date of registration: 20170727 Address after: 300000 Tianjin Nankai District 8 Alex Hua Tian Road, No. 302 North Haitai Information Plaza F Patentee after: Zhang Zhicai Address before: 266300 Department of Urology, Jiaozhou Central Hospital, Qingdao, Shandong, China Patentee before: Luan Jie |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20181123 Address after: 404500 Yunyang County Industrial Park, Chongqing Patentee after: Chongqing Sanxia Yunhai Pharmaceutical Co., Ltd. Address before: 300000 F North 302, Hai Tai Information Plaza, 8 Alex Hua Tian Road, Nankai District, Tianjin. Patentee before: Zhang Zhicai |
|
TR01 | Transfer of patent right | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20160427 Termination date: 20200530 |
|
CF01 | Termination of patent right due to non-payment of annual fee |